Short title: Regulation of galectin in the CL of mice Long summary statement: The differential effect of prolactin (PRL) and prostaglandin F 2 (PGF 2 ) on the expression of galectin-1 and galectin-3 in the mouse corpus luteum was analyzed using pregnant, postpartum, and non-pregnant cyclic mice.
Introduction
Galectin is a -galactoside-binding animal lectin involved in various physiological and pathological events regulating cell proliferation, differentiation, migration, and apoptosis. Fifteen members of galectin family have been identified in mammalian tissues, and the predominant subtypes expressed in the mouse ovary are galectin-1 and galectin-3 (Nio and Iwanaga 2007) . Recently, we demonstrated that both galectin subtypes in the corpus luteum (CL) of mice showed a stage-and cell-specific expression pattern during the estrous cycle, and their expression was especially intense in the regressing CL, which contains a progesterone degradation enzyme -20-hydroxysteroid dehydrogenase (20-HSD)-and abundant numbers of apoptotic cells (Nio-Kobayashi and Iwanaga 2010) . Although the characteristic expression of galectins in the regressing CL confirms their contribution to luteolysis, the function and regulation of galectin in the ovary remains unclear.
In rodents, luteolysis is characterized by an initial decline in progesterone secretion that is commonly designated as functional luteolysis, which is distinct from structural luteolysis that signifies the subsequent structural change with its gradual involution to form a small scar composed of connective tissue (Bachelot and Binart 2005) .
Functional luteolysis is accompanied by the expression of 20-HSD, whereas the structural luteolysis is characterized by apoptosis of luteal cells. CL function in rodents is regulated by two main factors: prolactin (PRL) from the pituitary gland and prostaglandin F 2 (PGF 2 ) from the uterus. PRL is a main luteotrophic hormone, and it induces gene expression essential for progesterone production, such as 3-hydroxysteroid dehydrogenase (3-HSD) and luteinizing hormone receptor (LH-R).
PRL also possesses a luteolytic role when the CL cease to produce progesterone by 4 expressing 20-HSD (Stocco et al. 2007) . It is currently believed that the pre-ovulatory surge of PRL on the evening of proestrus causes apoptosis of luteal cells, and thus structural luteolysis, in the CL during estrous cycles of non-pregnant mice (Gaytán et al. 2001 ). On the other hand, PGF 2 plays a crucial role in the functional luteolysis by inducing 20-HSD expression. 
Results

Effect of compulsorily weaning on galectin expression in the ovary of postpartum mice
Since postpartum ovulation occurs within 24 h after parturition, newly formed CL On the other hand, the expression of both galectins in the CLP was slightly reduced 48 h after the weaning (asterisks in Fig. 1F , G) and became intense at 72 h (asterisks in Fig. 1K , L), although the signals in the CLP were less intense than that in the CLN. The changes in the gene expression caused by compulsory weaning are summarized in Figure 1P and Q.
These observations indicate that an initial increase in galectin-1 expression in the CLN was accompanied by a decline in the expression of both 3-HSD and LH-R, implying a withdrawal of PRL stimulation by compulsory weaning. The further increase in galectin-1 72 h after the weaning was associated with intense expressions of 20-HSD and galectin-3. As the effect of compulsory weaning on galectin expression differed between in the CLN and CLP, and there was a time-lag in the expression of each galectin in the CLN of compulsorily weaned mice, the effect of PRL seems to differ with regards to galectin-1 and galectin-3 as well as to the status of the CL.
Effect of PGF 2 injection on galectin expression in the ovaries of pregnant and postpartum mice
It is well established that the synthesis of 20-HSD in rodent CL is regulated by PGF 2 possibly released from the uterus. As galectin-3 and 20-HSD are concomitantly expressed in the regressing CL (Nio and Iwanaga 2007), we hypothesized that galectin-3 would be also regulated by PGF 2 . To investigate this, we examined the effect of PGF 2 treatment on galectin-3 expression in the late CL of pregnancy (pregnancy day 17.5), which lacks both galectins and 20-HSD ( Fig. 2A-C ). Contrary to our expectations, PGF 2 administration did not induce galectin-3 expression in the 8 functional CLP of pregnant mice (Fig. 2B, F) , although 20-HSD expression was slightly increased by PGF 2 treatment in these CL (Fig. 2C, G ). There were no significant effect of PGF 2 on the expression of both galectin-1 ( Fig. 2A, E ) and LH-R in the functional CLP ( Fig. 2D, H) . On the other hand, when PGF 2 was administrated to postpartum mice at day 3, the expression of galectin-3 remarkably increased only in the remaining CLP, which intensely expressed 20-HSD but lacked LH-R (asterisks in 
Effect of Mifepristone (RU486) administration on galectin expression in the functional
CL of pregnancy
To clarify whether progesterone could influence galectin expression we administrated a progesterone receptor antagonist to mice at day 17.5 of pregnancy. There were no significant change in the expression of either galectin, 3-HSD, 20-HSD, or LH-R 12 h after Mifepristone treatment ( Fig. 3 , control were shown in Fig. 2A-D ), suggesting that PRL and/or PGF 2 may not indirectly regulate galectin expression via alternations in progesterone production.
Effect of Bromocriptine administration on the expression of galectins in the ovary of non-pregnant cyclic mice 9
As the increased expression of galectin-1 mRNA in weaned mice was accompanied by a reduction of 3-HSD and LH-R, which are known to be up-regulated by PRL, it is anticipated that a decrease in a PRL signal would induce the expression of galectin-1 in the CL. We therefore examined the effect of continuous administration of Bromocriptine, which suppresses the secretion of PRL from the pituitary gland, and the effect of an additional PRL treatment on luteal galectin expression. Because PRL is known to induce structural luteolysis when the CL cease progesterone production, we first expected that Bromocriptine treatment must prevent the CL from undergoing structural luteolysis. However, it does not influence on the rate of ovulation. Thus, the ovaries of the Bromocriptine-treated mice contained several generations of cyclic CL: the functional CL formed at the latest estrous cycle, and old regressing CL under functional but not structural regressing stage formed during previous estrous cycles.
The weight of the ovaries were significantly higher in the Bromocriptine-treated mice immunoreactions both for galectin-1 and galectin-3 than those in the old regressing CL.
These findings suggest that galectin-1 is negatively regulated by PRL but galectin-3 expression is not affected by PRL.
Discussion
Although the regulation of luteolysis is complicated and its exact mechanism remains to be elucidated, PRL and PGF 2 are likely to be main regulatory molecules of the CL function in mice. A remarkable change in the expression of galectin during the estrous cycle associated with an intense expression in the regressing CL suggests an involvement of galectin in the PRL and PGF 2 -regulated luteolysis. In this study, we found for the first time that PGF 2 was an excellent candidate for a molecular regulation of the expression both of galectin-1 and galectin-3 in the CL, although its effect was dependent on the status of the CL. When the CL intensely expressed LH-R, PGF 2 failed to induce the expression of either galectin. On the other hand, PRL seems to suppress the expression of galectin-1 but not that of galectin-3, suggesting differential regulatory mechanisms between galectin-1 and galectin-3 in the regressing CL.
As summarized in Fig. 5A , galectin-1 showed a biphasic expression pattern in the compulsorily weaned mice as previously reported by us in non-pregnant cyclic mice The expression of galectin-1 in the compulsorily weaned mice increased again more intensely in the CLN 72 h after the weaning and this was associated with a strong expression of 20-HSD (Fig. 5A) , which is known to be up-regulated by PGF 2 . As PGF 2 administration to the postpartum mice increased the expression of galectin-1 in the remaining CLP which lacked LH-R (Fig. 5B) , this second intense increase in galectin-1 mRNA with the intense expression of 20-HSD found in the CLN at 72 h after the weaning is likely to be caused by PGF 2 secreted from the uterus or the CL itself after a withdrawal of PRL stimulation.
Galectin-3 was also increased in the CLN of compulsorily weaned mice, however, its expression was observed later (at 72 h after the compulsory weaning) than an initial increase of galectin-1 in the CLN found at 48 h after the weaning (Fig. 5A ). This suggests that unlike galectin-1 the PRL withdrawal may not directly influence on the galectin-3 expression in the CLN. This idea is supported by the finding that the expression of galectin-3 was unaffected by Bromocriptine and PRL injection to non-pregnant cyclic mice. On the other hand, an increase of galectin-3 in the CLN at 13 72 h after compulsorily weaning was accompanied with an intense expression of 20-HSD, which is known to be induced by PGF 2 . Because PGF 2 administration to postpartum mice induced the expression of galectin-3 in the remaining CLP, PGF 2 is likely an excellent candidate to control the expression of galectin-3 as well as galectin-1 ( Fig. 5B) . It is known that PGF 2 functions via activation of the calcium and phospholipid-dependent protein kinase, protein kinase C (PKC) in human luteal cells (Abayasekara et al. 1993 ). In addition, in macrophages, PKC activator (phorbol myristate acetate) administration directly increased galectin-3 expression (Kim et al.
2003)
. Thus, PKC pathway may be an important cascade to induce the expression of galectin-3 as well as galectin-1 in the CL.
Notably, the PGF 2 -induced increase in galectin-3 as well as galectin-1 was only seen in the remaining CLP that lacked an expression of LH-R but not in the CLN with an intense expression of LH-R in the postpartum mice (Fig. 5B ). This suggests that the stimulating effect of PGF 2 , possibly via activation of PKC pathway, on the expression of galectins differs depending on the condition of the CL, particularly with regards to whether it is expressing LH-R or not. Similarly, PGF 2 administration to mice at pregnancy day 17.5 failed to increase the expression of either galectin-1 or galectin-3 in the functional CLP, which intensely expressed LH-R (Fig. 5B) . Thus, the up-regulation of galectin-3 as well as galectin-1 by PGF 2 may be blocked by the signal mediated through LH-R in the functional CLP of the pregnant mice and in the CLN of lactating postpartum mice (Fig. 5B) .
Since PRL and PGF 2 regulate luteal progesterone production through the regulation of the expression of 3-HSD, LH-R, and 20-HSD, it was considered that progesterone might be a candidate molecule involved in the regulation of galectin expression. However, the administration of Mifepristone, a progesterone receptor antagonist, had no effect on the galectin expression in the functional CLP of pregnant mice, suggesting that progesterone is not a key molecule for the regulation of luteal In conclusion, the expression of galectin in the mouse CL is differentially mediated by PRL and PGF 2 (Fig. 5 ). The expression of both galectin-1 and galectin-3 is induced by PGF 2 but the effect may be abolished if the CL is intensely expressing LH-R. On the other hand, PRL directly inhibits the expression of galectin-1 but not 15 that of galectin-3. As the expression of LH-R is up-regulated by PRL, a withdrawal of PRL stimulation is considered to be necessary for the PGF 2 -induced expression of galectins, especially for galectin-3. Although the mechanisms involved in the regulation of luteal galectin expression as well as its function are still not fully understood, the data presented here enhances the understanding the regulation of galectin not only in the CL but also potentially in other tissues under both physiological and pathological conditions.
Materials and methods
Animals and tissue sampling
Female ddY mice were purchased from Japan SLC (Shizuoka, Japan), and maintained under controlled light (12 hours light and 12 hours dark, lights-on at 8:30 a.m.) and temperature (20-22 °C) with free access to chow and tap water. All experiments using animals were approved by the local ethical committee of Hokkaido University (Approval no. 08-0054). At least three animals were used for each group and the similar results were obtained from all animals examined. The most representative data are shown in the results.
After natural labor at days 18.5 or 19.5 of pregnancy, mice were left to lactate for 3 days. On the morning of postpartum day 3 the pups were removed and the mothers were sacrificed 24, 48, and 72 h after the weaning by cardiac exanimation under deep anesthesia with pentobarbital, and fresh ovaries were obtained. Other mice were treated subcutaneously with PGF 2 (25 g in ethanol; Biomol International. L. P., PA) or Mifepristone (RU486; 25 mg/kg in ethanol; Sigma Chemical Company, MO) at day 17.5 of gestation, or at postpartum day 3, and sacrificed 12 h later for tissue collection.
In the experiments of Bromocriptine treatment, 8 week old females were subcutaneously administrated 5 IU of serum gonadotropin (Serotropin ® ; Aska Pharmaceutical Co. Ltd., Tokyo, Japan) followed 48 h later by an injection of 5 IU of human chorionic gonadotrophin (hCG; Gonatropin ® ; Aska Pharmaceutical Co. Ltd.) to synchronize the ovarian cycle. Commencing the following day (day 1), Bromocriptine (Parlodel ® , 5 mg/kg in 0.5% carboxymethylcellulose; Novartis Pharmaceutical Co. Ltd., Tokyo, Japan) was orally administrated twice a day for 10 days. On day 9, some mice were subcutaneously injected with sheep pituitary PRL (50 g in physiological saline;
Sigma Chemical Company). All mice treated with Bromocriptine or Bromocriptin plus PRL were sacrificed on day 10 for tissue collection. The ovaries obtained were immediately embedded in O.C.T. compound (Sakura Fintechnical Co., Ltd., Tokyo, Japan), snap frozen in liquid nitrogen, and stored at -30°C until use. For immunohistochemical analysis, the ovaries from Bromocriptine-and Bromocriptine plus PRL-treated mice were fixed with 4% paraformaldehyde at 4°C overnight.
In situ hybridization
Two non-overlapping 45-mer antisense oligonucleotide probes for galectin-1 (Lgals1), galectin-3 (Lgals3), 3-HSD (Hsd3b1), 20-HSD (Akr1c18), and LH-R (Lhcgr) were synthesized as reported previously (Nio and Iwanaga 2010). All probes were labeled with 33 P-dATP using terminal deoxynucleotidyl transferase (Invitrogen, Carlsbad, CA).
The procedure for in situ hybridization has been described previously (Nio et al. 2005) .
In brief, fresh frozen sections, 10 m-thick, were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer for 15 min and acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine-HCl (pH 8.0) for 10 min. Hybridization was performed at 42°C for 12 h by adding 10,000 cpm/L 33 P-labeled oligonucleotide probes. Then sections were rinsed at room temperature for 30 min in 2× SSC (1× SSC: 150 mM sodium chloride, 15 mM sodium citrate) containing 0.1% sarkosyl, immersed twice at 55°C for 40 min in 0.1× SSC containing 0.1% sarkosyl, dehydrated through a graded series of ethanol, and air-dried. Sections were exposed onto BioMax MR films (Kodak, Rochester, NY) for 1 day (for 3-HSD and 20-HSD) or for 10 days (for galectins and LH-R). The hybridized sections used for the exposure on X-ray films were stained with
Hematoxylin & Eosin and observed under a microscope to determine type of the CL. groups were analyzed using one-way ANOVA and differences were considered as significant when P<0.05.
In situ hybridization using two non-overlapping antisense probes exhibited consistent labeling in all tissues examined. Specificity of the hybridization was also confirmed by the disappearance of the signals with an excess dose of unlabeled antisense probes.
Immunohistochemistry
The paraformaldehyde-fixed ovaries were embedded in paraffin according to the conventional method. The sections were cut from these tissue blocks and the immunohistochemistry using specific antibodies for galectin-1 and galectin-3 was performed. The detailed procedure for immunohistochemistry was previously described (Nio-Kobayashi et al. 2010 ). 
Figure legends
